BioCentury
ARTICLE | Company News

Amgen considering risk-based Aimovig pricing

April 24, 2018 10:47 PM UTC

On a conference call to discuss 1Q18 earnings call, Amgen Inc. (NASDAQ:AMGN) EVP of Global Commercial Operation Anthony Hooper said the biopharma is "prepared to talk to payers about risk-based contracts with Aimovig."

This quarter, Amgen expects to launch migraine prevention candidate, which is under FDA review with a May 17 PDUFA date. Aimovig erenumab is a human mAb that inhibits the calcitonin gene-related peptide (CGRP) receptor. Amgen said Aimovig is poised to be a first-in-class CGRP antibody for the indication...

BCIQ Company Profiles

Amgen Inc.